Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. Cartography's ATLAS and SUMMIT drug discovery platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across the healthy body and large-scale profiling of individual cells from patient tumors. By leveraging petabytes of proprietary data, along with insights from machine learning and AI, Cartography is identifying and developing therapeutics against highly specific targets and target pairs to build a pipeline of molecules with the greatest patient impact. Cartography's lead program in preclinical development, CBI-1214, is a T-cell engager being advanced for CRC.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/02/25 | $67,000,000 | Series B |
8VC AME Cloud Ventures Amgen Ventures Andreessen Horowitz Artis Ventures Bio+Health Catalio Capital Management Finchley H.V. Gaingels Global BioAccess Fund LG Corp LOTTE Holdings Pfizer Venture Investments  Wing Venture Capital | undisclosed |
